CA3146050A1 - Compositions de dosage et procedes d'utilisation de composes psychedeliques - Google Patents

Compositions de dosage et procedes d'utilisation de composes psychedeliques Download PDF

Info

Publication number
CA3146050A1
CA3146050A1 CA3146050A CA3146050A CA3146050A1 CA 3146050 A1 CA3146050 A1 CA 3146050A1 CA 3146050 A CA3146050 A CA 3146050A CA 3146050 A CA3146050 A CA 3146050A CA 3146050 A1 CA3146050 A1 CA 3146050A1
Authority
CA
Canada
Prior art keywords
formulation
psychedelic
dmt
combinations
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3146050A
Other languages
English (en)
Inventor
Craig Michael ARNOLD
Parag BHATT
Scott SLAY
Michael S. Hartman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sw Holdings Inc
Original Assignee
Sw Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sw Holdings Inc filed Critical Sw Holdings Inc
Publication of CA3146050A1 publication Critical patent/CA3146050A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouvelles compositions de dosage et des procédés d'utilisation comprenant au moins un composé psychedélique dérivé d'organismes vivants tels que des plantes et des champignons, des formes dérivées synthétiquement ou un analogue synthétique. La composition est destinée à être utilisée dans des systèmes d'administration à dosage, notamment un aérosol nasal, un aérosol-doseur pressurisé, etc.
CA3146050A 2019-07-04 2020-07-03 Compositions de dosage et procedes d'utilisation de composes psychedeliques Pending CA3146050A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962870722P 2019-07-04 2019-07-04
US62/870,722 2019-07-04
PCT/US2020/040826 WO2021003467A1 (fr) 2019-07-04 2020-07-03 Compositions de dosage et procédés d'utilisation de composés psychédéliques

Publications (1)

Publication Number Publication Date
CA3146050A1 true CA3146050A1 (fr) 2021-01-07

Family

ID=74100817

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3146050A Pending CA3146050A1 (fr) 2019-07-04 2020-07-03 Compositions de dosage et procedes d'utilisation de composes psychedeliques

Country Status (3)

Country Link
US (1) US20220304980A1 (fr)
CA (1) CA3146050A1 (fr)
WO (1) WO2021003467A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202003059D0 (en) * 2020-03-03 2020-04-15 Beckley Found Compounds for use in a method of treating, preventing and/or reducing the symptoms of pain
WO2021226416A1 (fr) 2020-05-08 2021-11-11 Psilera Inc. Nouvelles compositions de matière et compositions pharmaceutiques
EP4153564A1 (fr) 2020-05-19 2023-03-29 Cybin IRL Limited Dérivés de tryptamine deutérés et procédés d'utilisation
CN116056762A (zh) * 2020-06-12 2023-05-02 贝克利心理科技有限公司 包含5-甲氧基-n,n-二甲基色胺的苯甲酸盐的组合物
IL299453A (en) 2020-06-17 2023-02-01 Psilo Scient Ltd Extraction and composition of psychoactive alkaloids with inhibited dephosphorylation
CA3197443A1 (fr) * 2020-12-28 2022-06-28 Psilo Scientific Ltd. Procedes d'extraction d'alcaloides psychoactifs et preparation connexe en formes transmucosales
US20220265582A1 (en) * 2021-02-24 2022-08-25 Universitätsspital Basel Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy
US20220280482A1 (en) * 2021-03-06 2022-09-08 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
WO2022212789A1 (fr) * 2021-03-31 2022-10-06 Mycrodose Therapeutics Inc. Système transdermique, formulation et méthode d'administration thérapeutique d'un agent psychédélique
WO2022221554A2 (fr) * 2021-04-16 2022-10-20 Callitas Health Inc. Compositions et procédés pour l'administration de psilocine et de promédicaments de celle-ci
IL308074A (en) 2021-04-26 2023-12-01 Atai Therapeutics Inc Preparations containing N,N-DIMETHYLTRYPTAMINE and their uses
JP2024517194A (ja) * 2021-05-03 2024-04-19 マインド メディシン， インコーポレイテッド サイケデリック薬の用量を漸増する方法
US11877986B1 (en) * 2021-05-12 2024-01-23 Trucelium Inc Method of precision dosing
CA3216799A1 (fr) * 2021-05-17 2022-11-24 Alex Nivorozhkin Formulations de psilocybine
WO2023012691A1 (fr) * 2021-08-03 2023-02-09 Pike Therapeutics, Inc. Administration posologique transdermique d'agents pharmaceutiques
CA3231021A1 (fr) * 2021-09-08 2023-03-16 Michael Palfreyman Associations medicamenteuses
EP4159202A1 (fr) * 2021-09-29 2023-04-05 Biomind Labs Inc Formulation pharmaceutique contenant une substance psychédélique obtenue par impression 3d par frittage laser sélectif (sls)
EP4159192A1 (fr) * 2021-09-30 2023-04-05 Biomind Labs Inc Spray nasal à base de diméthyltriptamine pour le traitement personnalisé des troubles neurologiques et psychiatriques
EP4159201A1 (fr) 2021-09-30 2023-04-05 Biomind Labs Inc Nanoparticules encapsulées et nanoparticules de diméthyltriptamines
WO2023115060A1 (fr) * 2021-12-17 2023-06-22 The Regents Of The University Of California Psychoplastogènes pour le traitement de troubles auditifs
WO2023214404A1 (fr) * 2022-05-01 2023-11-09 Short Wave Pharma Inc. Film mucoadhésif comprenant un agent pharmaceutiquement actif et ses utilisations
WO2024028779A1 (fr) * 2022-08-01 2024-02-08 Psyched Wellness Ltd. Formulations et dispositifs de vaporisateur d'amanite tue-mouche
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
WO2024079648A1 (fr) * 2022-10-11 2024-04-18 Sintalica S.R.L. Système d'administration pour la libération contrôlée d'un composé psychédélique, composition pharmaceutique et utilisations associées

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8785500B2 (en) * 2006-03-22 2014-07-22 Icahn School Of Medicine At Mount Sinai Intranasal administration of ketamine to treat depression
JP6339371B2 (ja) * 2011-03-03 2018-06-06 インペル ニューロファーマ インコーポレイテッド 経鼻薬物送達デバイス
ES2898173T3 (es) * 2014-06-30 2022-03-04 Syqe Medical Ltd Dispositivos y sistemas para la administración pulmonar de principios activos
WO2017184531A1 (fr) * 2016-04-18 2017-10-26 Demerx, Inc. Traitement de troubles liés au mouvement au moyen de la noribogaïne
NL2018190B1 (en) * 2017-01-18 2018-07-26 Procare Beheer B V Psilocybin or psilocin in combination with cannabinoid

Also Published As

Publication number Publication date
US20220304980A1 (en) 2022-09-29
WO2021003467A1 (fr) 2021-01-07

Similar Documents

Publication Publication Date Title
CA3146050A1 (fr) Compositions de dosage et procedes d'utilisation de composes psychedeliques
US11844763B2 (en) Pharmaceutical composition and method of manufacturing
US10632266B2 (en) Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same
JP6941224B2 (ja) 疾患の処置のための鼻腔内エピネフリン製剤及び方法
US10045976B2 (en) Nicotine-containing liquid formulations and uses thereof
ES2332405T3 (es) Una composicion de nicotina liquida tamponada para administracion pulmonar.
Wise et al. Sweet taste and menthol increase cough reflex thresholds
US20210077382A1 (en) Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions
US20050241658A1 (en) Composition to reduce or quit smoking addiction
AU2010360967B2 (en) Nicotine containing formulation
UA126849C2 (uk) Нікотинові композиції для інгаляції та способи їх виготовлення та використання
JP2019520361A (ja) アルコール使用障害の処置のための組成物、装置、及び、方法
CN103948573A (zh) 一种可镇静助眠和缓解心悸的芳冰鼻用制剂的制备
US20200009126A1 (en) Tobacco- and smoke-less products consumable by humans as epicurean or medical products and method of treating smoking addiction
US20220305223A1 (en) Olfactory Delivery Device, System and Method for the Delivery of a Variety of Pharmaceutical Agents
US10610483B2 (en) Vaporized medicants and methods of use
Alexander Dosage forms and their routes of administration
JP7492548B2 (ja) アルコール使用障害の処置のための組成物、装置、及び、方法
US20220175755A1 (en) Methods of treating tobacco smoking addiction, and treating nicotine and tobacco smoking addiction
WO2006004418A2 (fr) Tabac en capsule
Abinaya Formulation Development of Dry Powder Inhalation of Amino Acids for Smoking Cessation
BR112020015646A2 (pt) Formulações intranasais de epinefrina e métodos para o tratamento de doença